Stock·NASDAQ·Healthcare
Orthofix Medical Inc. (OFIX)
- Market cap
- $387.64M
- Dividend yield
- 0.00%
- Street target
- $13.00median of 5 analysts
- 52-week range
- $8.50 $16.99
The short version
Where OFIX stands today, in four lines, and what CleaRank Financial AI makes of it.
OFIX at a glance
Orthofix Medical Inc. (OFIX): Buy, 70/100 on CleaRank's AI score.
- Trend Mixed: the price is above its 50-day but below its 200-day moving average ($9.50 and $11.40).
- Earnings OFIX beat estimates in 4 of its last 4 quarters, yet fell the next day after 1 of those beats.
- Insiders Insiders sold $3.6M and bought $8.3M over the last 18 months.
Figures as of October 16, 2026.
CleaRank Financial AI
Orthofix Medical Inc. (OFIX) is currently trading at $9.59, slightly above its 50-day simple moving average of $9.50 but below its 200-day SMA of $11.40.
The company has demonstrated a pattern of positive earnings surprises in recent quarters, with the latest results reported on August 5, 2026, showing an EPS beat of 333.33%. Insiders have been net buyers, with total purchases of $8.3 million versus $3.6 million in sales, indicating moderate accumulation. Wall Street analysts maintain a 'Buy' consensus with a median price target of $13.00, implying a 35.6% upside from the current price. While the company's profit margin is negative at -7.41%, its revenue growth has been positive at 3.8%, and its price-to-sales ratio of 0.45 is below the sector median of 3.4. The company's debt-to-equity ratio stands at 0.61, aligning with the sector average.
Only on CleaRank
Figures we compute ourselves from OFIX's own price, earnings and insider-filing history. Tap one to see it in context.
Price and trading
The chart, today's range and how far the price has moved over each period.
Trend checks
1/4Price above its 50-day average ›
The price of $9.59 is 0.9% above the 50-day simple moving average of $9.50.Price above its 200-day average ›
The price is 15.9% below the 200-day simple moving average of $11.40.50-day average above the 200-day ›
The 50-day average ($9.50) is 16.7% below the 200-day average ($11.40), the arrangement of a falling longer-term trend.In the upper half of its 52-week range ›
The price sits at 13% of its 52-week range, between $8.50 and $16.99.
OFIX share price
Pick a period: each tab shows how far OFIX has moved over it, to the last close.
Today's trading
Where OFIX sits inside today's range and its 52-week range.
Fundamentals
Valuation against the sector, and the revenue and earnings behind it.
Valuation and quality checks
2/3P/S below the sector median ›
The price-to-sales ratio of 0.45 is 86.8% below the sector median of 3.4.Profitable over the last 12 months ›
Net income over the last 12 months was $-61.7M on revenue of $833.2M, a net margin of -7.4%.Beat estimates in most recent reports ›
OFIX beat the EPS estimate in 4 of its last 4 reports.
Key statistics
The headline figures for OFIX.
As of October 16, 2026, OFIX trades at $9.59, with a market value of $387.64M and no P/E ratio (its trailing earnings are negative).
What the numbers say
CleaRank Financial AI's reading of OFIX's valuation, growth and risks.
Orthofix Medical Inc. (OFIX) exhibits a price-to-sales ratio of 0.45, which is significantly below the sector median of 3.4, suggesting potential undervaluation on a revenue basis.
However, the company is currently loss-making, with a negative profit margin of -7.41% and a negative EPS of -1.52. Its return on equity is also negative at -13.91%. The company's revenue growth stands at 3.8%, which is below the sector average of 8.1%. The debt-to-equity ratio is 0.61, which is in line with the sector median. Despite the current profitability challenges, the below-sector-average price-to-sales ratio and positive revenue growth warrant attention.
OFIX against the Healthcare sector
How OFIX compares with the median Healthcare stock CleaRank tracks.
Price to sales vs sector: On price-to-sales, the yardstick used here in place of P/E, OFIX trades at 0.4488x, far below the sector average of 3.40x.
Return vs XLV: Since May 5, 2025, OFIX has lost 29.2% against a gain of 28.9% for XLV.
Performance against XLV
OFIX and the Healthcare sector fund over the same days.
Revenue and earnings
How much OFIX sells, and how much of it becomes profit.
Revenue growth: Revenue grew 2.9% in FY2025 to $822M, from $799M a year earlier.
Profit margin: The net margin was -11.2% in FY2025, up from -15.8% the year before.
Profitable: OFIX lost $92.2M in FY2025.
Earnings reality check
Did OFIX beat what analysts expected, and how did the stock react?
Earnings record: OFIX beat the analyst estimate in 4 of the last 4 quarters.
Market reaction: The stock fell in the first session after 1 of those 4 beats, so a beat has not been enough on its own.
| Report | Estimate | Actual | Surprise | First session | 5 sessions |
|---|---|---|---|---|---|
| Aug 5, 2026after close | -$0.03 | $0.07 | +333.33% | +1.73% | -0.19% |
| May 5, 2026after close | -$0.29 | -$0.11 | +62.07% | -2.01% | -2.09% |
| Nov 4, 2025after close | $0.12 | $0.20 | +66.67% | +0.67% | +3.43% |
| Aug 5, 2025after close | $0.04 | $0.13 | +225.00% | +1.87% | +12.10% |
As of October 16, 2026, OFIX has beaten the analyst EPS estimate in 4 of its last 4 reported quarters and fell in the first trading session after 1 of those beats; its latest report, on August 5, 2026, came in 333.33% above the estimate and the stock moved +1.73% in the first session.
The first session is the first full trading day on the news: the report day itself for a report before the open, the next day for one after the close. Surprise is actual EPS against the consensus estimate.
AI analysis and technicals
CleaRank's score and reasoning, the indicators behind it, and what the price moves with.
Momentum checks
2/3RSI not overbought or oversold ›
The 14-day RSI is 55.2, in neutral territory.RSI above 50 ›
An RSI of 55.2 is above the 50 midpoint, so buyers have had the upper hand over the last 14 days.MACD line above zero ›
The MACD line is negative, so the 12-day average is below the 26-day average.
CleaRank AI analysis of OFIX
The score, the reasoning behind it, and what could move the price next.
Orthofix Medical Inc. (OFIX) is trading above its 50-day SMA of $9.50 and its 20-day EMA of $9.31, but remains below its 200-day SMA of $11.40.
The 14-day RSI is at 55.18, indicating neutral momentum, while the Stochastic indicator is at 72.28, suggesting it is approaching overbought territory. The current price of $9.59 is supported by the 50-day SMA, with the next resistance level identified at the 200-day SMA of $11.40. Volume has been below its average, down 21.9%, which may suggest a lack of strong conviction behind recent price movements. The CCI at 86.49 indicates bullish sentiment.
Consistent EPS Beats ›
Orthofix Medical Inc. (OFIX) has demonstrated a pattern of beating EPS estimates in recent quarters, notably a 333.33% surprise in the latest report, which could drive positive price momentum.
Source: Earnings ReportsInsider Net Buying Activity ›
Significant insider purchases totaling $8.3 million versus $3.6 million in sales indicate a moderate level of confidence from management and key stakeholders.
Source: Insider TransactionsWall Street 'Buy' Consensus and Price Target ›
With 5 analysts covering OFIX, the consensus is 'Buy' and the median price target of $13.00 suggests a potential 35.6% upside from the current price.
Source: Analyst Ratings
Medical Device Sector Performance ›
The performance of the broader medical device sector, represented by ETFs like XLV, will influence Orthofix Medical Inc.'s (OFIX) stock movement.
Source: Sector Analysis
- The stock is trading near its 50-day SMA, suggesting a potential short-term inflection point; watch for a decisive move above the 200-day SMA at $11.40 to confirm a bullish trend reversal.
Technical indicators
Momentum and trend for OFIX, from its daily closes.
As of October 16, 2026, with OFIX at $9.59, its 14-day RSI is 55.2 (neutral territory), its 50-day simple moving average is $9.50 and its 200-day is $11.40.
Calculated by CleaRank on daily closes as of October 16, 2026: Wilder's 14-day RSI, 50- and 200-day simple moving averages, MACD line (12, 26).
What OFIX moves with
Correlation of daily returns over one year: +1 moves in step, 0 has no link, -1 moves the opposite way.
As of October 16, 2026, OFIX's 1-year correlation of daily returns is +0.33 with S&P 500 (SPY), +0.24 with Nasdaq 100 (QQQ), +0.05 with Bitcoin (BTC) and -0.05 with gold (XAU).
What Wall Street expects
The analysts' target range and how their ratings split.
Analysts checks
2/3Most analysts rate it a buy ›
3 of 5 analysts rate it a buy or strong buy, 2 a hold and 0 a sell.Median target above the price ›
The median 12-month target of $13.00 is 35.6% above the price.More buy ratings than three months ago ›
3 of 5 rate it a buy now, against 3 of 5 three months ago.
OFIX Wall Street View
12-month price targets
The price, $9.59, sits below every analyst's target.
Ratings
Recent rating actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Aug 10, 2026 | Canaccord Genuity | Maintains | Buy |
| Jul 6, 2026 | Barrington Research | Maintains | Outperform |
| May 22, 2026 | Canaccord Genuity | Maintains | Buy |
| May 22, 2026 | Barrington Research | Maintains | Outperform |
| May 22, 2026 | Stifel | Maintains | Buy |
As of October 16, 2026, 5 Wall Street analysts cover OFIX: 3 rate it a buy or strong buy, 2 a hold and 0 a sell or strong sell. Their 12-month price targets range from $12.00 to $14.00, with a median of $13.00, 35.6% above the price of $9.59.
Source: TwelveData analyst consensus. Targets and ratings belong to the analysts, not to CleaRank.
A trade plan, if you want one
Entry, stop and target levels from the moving averages and recent volatility. Educational, not advice.
OFIX trade plan
Entry, stop and target levels, sized to your account. Change the bias or the risk and every level updates.
Long entry pick an entry style
Risk management
Profit targets (Based on Conservative Entry)
These levels come from OFIX's moving averages and recent volatility, not from a forecast. Educational levels, not financial advice; the full disclaimer is at the foot of the page.
Risk profile
How much OFIX tends to move, against the market and on its own.
The long record
OFIX's worst falls and recoveries, what $10,000 became, and which months have been kind to it.
Track record checks
0/4Average daily move under 2% ›
The price has moved 2.27% on an average day (30-day standard deviation of daily returns).Recovered from its worst fall ›
The worst fall was 86.8%, from February 2019 to September 2026; the price is still 85.4% below that peak.Most 1-year holds ended higher ›
31% of 1-year holding periods in the last 10 years ended with a gain.Beat the S&P 500 since the chart begins ›
$10,000 invested in October 2016 is now worth $2,405.32, against $42,525 in the S&P 500 (SPY).
OFIX Drawdowns & Recovery
As of October 16, 2026, OFIX's worst peak-to-trough fall over the last 10 years with dividends reinvested was -86.8% (February 2019 to September 2026); it is still 85.4% below that peak, and 31% of 1-year holding periods ended with a gain.
From weekly closing values with dividends reinvested. A drawdown is the fall from the highest value reached so far to a later low.
Growth of $10,000
What $10,000 put into OFIX in October 2016 is worth now, against the same amount in the S&P 500.
Against the market: OFIX trailed the S&P 500 over this period: $2,405.32 against $42,525.
A $10,000 investment in OFIX in October 2016 would be worth about $2,405 today with dividends reinvested, compared with about $42,525 for the same investment in the S&P 500 benchmark (also with dividends reinvested).
Seasonal patterns
Which calendar months have been kind to OFIX, and which have not.
Strongest month, November: an average of +6.25%, up in 9 of 10 years.
Weakest month, March: an average of -7.72%, up in 3 of 10 years.
This month, October: has averaged -4.58%, up in 5 of 9 years. Past seasonality does not repeat on schedule.
Over the last 10 years, OFIX's strongest calendar month has been November (average +6.25%, up in 9 of 10 years) and its weakest March (average -7.72%, up in 3 of 10 years).
Average return for each calendar month over the last 10 years, from weekly closing prices with dividends included.
Long-term scenarios
Thousands of simulated paths from the price history. A range of outcomes, not a forecast.
Monte Carlo projection
Thousands of simulated paths for $10,000 in OFIX, from its own past volatility. The shaded area holds 80% of them.
CleaRank's 10-year Monte Carlo simulation projects that a $10,000 investment in OFIX today could grow to about $6,277 by 2036 in the base case, with a 90th-percentile outcome near $34,155 and a 10th-percentile outcome around $1,154. Projections are statistical simulations, not guarantees.
OFIX Stock Price Prediction: 2030
The same simulation in share prices, year by year.
CleaRank's simulation projects a price near $7.96 for OFIX by 2030 in the base case, from $9.59 today (0.8x over 4 years). The 10th-percentile path ends near $2.73. These are outcomes of a Monte Carlo simulation run on OFIX's historical return distribution, not price targets, and they assume no dividends are reinvested.
| Year | 10th percentile | Base case | 90th percentile | range base today |
|---|---|---|---|---|
| 2027 | $5.36 | $9.15 | $15.64 | |
| 2028 | $4.10 | $8.74 | $18.64 | |
| 2029 | $3.30 | $8.34 | $21.09 | |
| 2030 | $2.73 | $7.96 | $23.24 | |
| 2031 | $2.29 | $7.60 | $25.17 |
Method: a lognormal simulation of OFIX's own volatility and capped historical trend, re-run daily; base case is the median path, the outer columns the 10th and 90th percentiles.
Insider trading
What the people running the company have bought and sold.
OFIX insider trading
Shares the company's directors and officers bought and sold, from their own filings.
Month by month
Open-market purchases above the line, sales below.
Insider buying: Insiders bought $8.3M on the open market and sold $3.6M.
As of October 16, 2026, OFIX insiders reported 19 open-market sales worth $3.6M and 10 open-market purchases worth $8.3M over the last 18 months; grants and option exercises are not counted.
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| Oct 1, 2026 | Patrick G Fisher
Officer
|
Sell | 150 | $1.4K |
| Sep 21, 2026 | Juniper Investment Company, Llc
Beneficial Owner of more than 10% of a Class of Security
|
Buy | 310.0K | $2.7M |
| Sep 1, 2026 | Patrick G Fisher
Officer
|
Sell | 150 | $1.4K |
| Aug 18, 2026 | Patrick G Fisher
Officer
|
Sell | 1.3K | $13.1K |
| Jun 18, 2026 | Aviva Mcpherron
Officer
|
Sell | 3.7K | $34.4K |
| Jun 10, 2026 | Alan Lee Bazaar
Director
|
Grant | 15.0K | - |
| Jun 10, 2026 | Wayne C. Burris
Director
|
Grant | 15.0K | - |
| Jun 10, 2026 | Vickie Lynn Capps
Director
|
Grant | 15.0K | - |
| Jun 10, 2026 | Michael M Finegan
Director
|
Grant | 20.7K | - |
| Jun 10, 2026 | Jason M Hannon
Director
|
Grant | 15.0K | - |
| Jun 10, 2026 | John Bell Henneman III
Director
|
Grant | 15.0K | - |
| Jun 10, 2026 | Charles R Kummeth
Director
|
Grant | 15.0K | - |
| Jun 10, 2026 | Shweta Singh Maniar
Director
|
Grant | 15.0K | - |
| Jun 10, 2026 | Michael E Paolucci
Director
|
Grant | 15.0K | - |
| May 22, 2026 | Juniper Investment Company, Llc
Beneficial Owner of more than 10% of a Class of Security
|
Sell | 242.0K | $2.6M |
| May 7, 2026 | Engine Capital Management, L.l.c.
Beneficial Owner of more than 10% of a Class of Security
|
Buy | 184.9K | $2.2M |
| May 7, 2026 | John Bell Henneman III
Director
|
Buy | 5.0K | $61.3K |
| Apr 16, 2026 | Jorge Andres Cedron
Officer
|
Sell | 3.7K | $48.0K |
| Mar 17, 2026 | Lucas S Vitale
Chief Operating Officer
|
Sell | 4.3K | $50.9K |
| Mar 10, 2026 | Vickie Lynn Capps
Director
|
Buy | 5.0K | $62.3K |
| Mar 5, 2026 | Massimo Calafiore
Chief Executive Officer
|
Sell | 12.2K | $155.6K |
| Mar 5, 2026 | Julie Andrews
Chief Financial Officer
|
Sell | 4.8K | $61.0K |
| Mar 5, 2026 | Jorge Andres Cedron
Officer
|
Sell | 2.8K | $35.3K |
| Mar 5, 2026 | Aviva Mcpherron
Officer
|
Sell | 2.6K | $32.6K |
| Mar 5, 2026 | Lucas S Vitale
Chief Operating Officer
|
Sell | 2.3K | $29.4K |
| Mar 5, 2026 | Max Reinhardt
Officer
|
Sell | 2.1K | $27.2K |
| Mar 5, 2026 | Patrick G Fisher
Officer
|
Sell | 1.5K | $19.6K |
| Mar 3, 2026 | Julie Andrews
Chief Financial Officer
|
Grant | 35.5K | - |
| Mar 3, 2026 | Massimo Calafiore
Chief Executive Officer
|
Grant | 115.1K | - |
| Mar 3, 2026 | Jorge Andres Cedron
Officer
|
Grant | 23.0K | - |
| Mar 3, 2026 | Patrick G Fisher
Officer
|
Grant | 21.1K | - |
| Mar 3, 2026 | Aviva Mcpherron
Officer
|
Grant | 23.0K | - |
| Mar 3, 2026 | Lucas S Vitale
Officer
|
Grant | 19.2K | - |
| Feb 25, 2026 | Engine Capital Management, L.l.c.
Beneficial Owner of more than 10% of a Class of Security
|
Buy | 137.9K | $1.7M |
| Jan 16, 2026 | Julie Andrews
Chief Financial Officer
|
Sell | 4.9K | $70.1K |
| Jan 12, 2026 | Massimo Calafiore
Chief Executive Officer
|
Sell | 19.4K | $301.0K |
| Aug 18, 2025 | Patrick G Fisher
Officer
|
Sell | 2.0K | $28.4K |
| Jul 2, 2025 | Engine Capital Management, L.l.c.
Beneficial Owner of more than 10% of a Class of Security
|
Buy | 1.3K | $13.9K |
| Jun 18, 2025 | Aviva Mcpherron
Officer
|
Sell | 3.7K | $39.2K |
| Jun 18, 2025 | Alan Lee Bazaar
Director
|
Grant | 18.8K | - |
| Jun 18, 2025 | Wayne C. Burris
Director
|
Grant | 18.8K | - |
| Jun 18, 2025 | Vickie Lynn Capps
Director
|
Grant | 18.8K | - |
| Jun 18, 2025 | Michael M Finegan
Director
|
Grant | 26.1K | - |
| Jun 18, 2025 | Jason M Hannon
Director
|
Grant | 18.8K | - |
| Jun 18, 2025 | John Bell Henneman III
Director
|
Grant | 18.8K | - |
| Jun 18, 2025 | Charles R Kummeth
Director
|
Grant | 18.8K | - |
| Jun 18, 2025 | Shweta Singh Maniar
Director
|
Grant | 18.8K | - |
| Jun 18, 2025 | Michael E Paolucci
Director
|
Grant | 18.8K | - |
| Jun 11, 2025 | Max Reinhardt
Officer
|
Sell | 1.6K | $19.1K |
| Jun 4, 2025 | Alan Lee Bazaar
Director
|
Buy | 2.3K | $24.6K |
| May 12, 2025 | Alan Lee Bazaar
Director
|
Buy | 4.0K | $50.3K |
| May 9, 2025 | Massimo Calafiore
Chief Executive Officer
|
Buy | 10.0K | $125.4K |
| May 7, 2025 | Engine Capital Management, L.l.c.
Beneficial Owner of more than 10% of a Class of Security
|
Buy | 100.0K | $1.2M |
Source: TwelveData, from SEC Form 4 filings
Questions people ask
Answered from the figures on this page, as of October 16, 2026.